Activity of ipilimumab at 10mg/kg in patients with advanced melanoma is independent of baseline prognostic factors

被引：4

作者：

Schadendorf, D. ^{[1
]}

Wolchok, J. ^{[2
]}

Neyns, B. ^{[3
]}

Lebbe, C. ^{[4
]}

Harmankaya, K. ^{[5
]}

Verschraegen, C. ^{[6
]}

Chin, K. ^{[7
]}

de Pril, V. ^{[8
]}

Hoos, A. ^{[7
]}

Maio, M. ^{[9
]}

机构：

[1] Univ Hosp Essen, Dept Dermatol, Essen, Germany

[2] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA

[3] Univ Ziekenhuis St Rafael, Dept Oncol, Brussels, Belgium

[4] Hop St Louis, Dept Dermatol, Paris, France

[5] Med Univ Vienna, Dept Dermatol, Vienna, Austria

[6] Univ New Mexico, Canc Res & Treatment Ctr, Albuquerque, NM 87131 USA

[7] Bristol Myers Squibb Co, Global Clin Res Oncol, Wallingford, CT 06492 USA

[8] Bristol Myers Squibb Co, Global Biometr & Sci, Braine Lalleud, Belgium

[9] Univ Hosp Siena, Dept Oncol, Siena, Italy

来源：

EJC SUPPLEMENTS | 2009年 / 7卷 / 02期

关键词：

D O I：

10.1016/S1359-6349(09)71952-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：579 / 579

页数：1

共 50 条

[1] Efficacy of ipilimumab 10 mg/kg in advanced melanoma patients (pts) with good and poor prognostic factors
Wolchok, J. D.
de Pril, V.
Linette, G.
Waterfield, W.
Gajewski, T.
Chiarion-Sileni, V.
Ibrahim, R.
Chin, K.
Hoos, A.
Hamid, O.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[2] Neoadjuvant combination immunotherapy with ipilimumab (3 mg/kg or 10mg/kg) and high dose IFN-a2b in locally/regionally advanced melanoma.
Tarhini, Ahmad A.
Rahman, Zahra
Lin, Yan
Vallabhaneni, Priyanka
Tawbi, Hussein Abdul-Hassan
Gnan, Andrew
McFadden, Amanda
Rose, Amy
Pruckner, Chelsea
Wilson, Melissa
Pingpank, James F.
Holtzman, Matthew Peter
Ferris, Robert L.
Rao, Uma N. M.
Kirkwood, John M.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[3] Immunological profiling of baseline and resected biopsies from locally/regionally advanced/recurrent melanoma treated with neoadjuvant combination ipilimumab (3mg/kg or 10mg/kg) and high dose IFN-α2B
Warren, Sarah
Vallabhaneni, Priyanka
El-Sawada, Jack
White, Andrew
Ren, Xing
Cesano, Alessandra
Beechem, Joseph
Tarhini, Ahmad
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
[4] IPILIMUMAB 10 MG/KG INDUCTION DOSING PROMOTES T-CELL ACTIVATION IN PATIENTS WITH ADVANCED MELANOMA
Hoos, A.
Chasalow, S. D.
Parker, S. M.
Siegel, J.
Tsuchihashi, Z.
Wu, D.
Bennett, K.
Alaparthy, S.
Ronczka, A.
Berman, D.
ANNALS OF ONCOLOGY, 2008, 19 : 244 - 244
[5] Myeloid-derived suppressor cell quantity prior to treatment with ipilimumab at 10mg/kg to predict for overall survival in patients with metastatic melanoma
Kitano, Shigehisa
Postow, Michael Andrew
Cortez, Czrina
Rasalan, Teresa
Gallardo, Humilidad F.
Panageas, Katherine
Yuan, Jianda
Wolchok, Jedd D.
Lesokhin, Alexander M.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[6] Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
Ascierto, Paolo Antonio
Del Vecchio, Michele
Mackiewicz, Andrzej
Robert, Caroline
Chiarion-Sileni, Vanna
Arance, Ana
Lebbe, Celeste
Svane, Inge Marie
McNeil, Catriona
Rutkowski, Piotr
Loquai, Carmen
Mortier, Laurent
Hamid, Omid
Bastholt, Lars
Dreno, Brigitte
Schadendorf, Dirk
Garbe, Claus
Nyakas, Marta
Grob, Jean-Jacques
Thomas, Luc
Liszkay, Gabriella
Smylie, Michael
Hoeller, Christoph
Ferraresi, Virginia
Grange, Florent
Gutzmer, Ralf
Pikiel, Joanna
Hosein, Fareeda
Simsek, Burcin
Maio, Michele
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
[7] Neoadjuvant ipilimumab (3mg/kg or 10mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire
Tarhini, Ahmad
Lin, Yan
Lin, Huang
Rahman, Zahra
Vallabhaneni, Priyanka
Mendiratta, Prateek
Pingpank, James F.
Holtzman, Matthew P.
Yusko, Erik C.
Rytlewski, Julie A.
Rao, Uma N. M.
Ferris, Robert L.
Kirkwood, John M.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
[8] Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
Ascierto, Paolo A.
Del Vecchio, Michele
Robert, Caroline
Mackiewicz, Andrzej
Chiarion-Sileni, Vanna
Arance, Ana
Lebbe, Celeste
Bastholt, Lars
Hamid, Omid
Rutkowski, Piotr
McNeil, Catriona
Garbe, Claus
Loquai, Carmen
Dreno, Brigitte
Thomas, Luc
Grob, Jean-Jacques
Liszkay, Gabriella
Nyakas, Marta
Gutzmer, Ralf
Pikiel, Joanna
Grange, Florent
Hoeller, Christoph
Ferraresi, Virginia
Smylie, Michael
Schadendorf, Dirk
Mortier, Laurent
Svane, Inge Marie
Hennicken, Delphine
Qureshi, Anila
Maio, Michele
LANCET ONCOLOGY, 2017, 18 (05): : 611 - 622
[9] Overall survival at 5 years of follow-up from a phase 3 trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
Ascierto, Paolo A.
Del Vecchio, Michele
Mackiewicz, Andrzej
Robert, Caroline
Chiarion-Sileni, Vanna
Arance, Ana
Lebbe, Celeste
Svane, Inge Marie
McNeil, Catriona
Rutkowski, Piotr
Loquai, Carmen
Mortier, Laurent
Hamid, Omid
Bastholt, Lars
Dreno, Brigitte
Schadendorf, Dirk
Garbe, Claus
Nyakas, Marta
Grob, Jean-Jacques
Thomas, Luc
Liszkay, Gabriella
Smylie, Michael
Burcin, Simsek
Hosein, Fareeda
Maio, Michele
JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17
[10] SAFETY AND EFFICACY OF IPILIMUMAB 10 MG/KG AMONG PATIENTS WITH ADVANCED MELANOMA FROM ITALY ENROLLED IN A EUROPEAN COMPASSIONATE USE PROGRAM
Maio, M.
Queirolo, P.
Testori, A.
Altomonte, M.
Maur, M.
Bajetta, E.
Ascierto, P. A.
Sileni, V. Chiarion
Di Giacomo, A. M.
Ridolfi, R.
ANNALS OF ONCOLOGY, 2012, 23 : 373 - 374

← 1 2 3 4 5 →